Edison Oncology Holding

Phase 2 oncology biotech Edison Oncology Holding files and sets terms for a $25 million IPO   Edison Oncology Holding, a Phase 2 biotech developing targeted small-molecule oncology therapies, filed on Friday with the SEC to raise up to $25... Read more